Información del artículo
Resumen
La mortalidad de pacientes en estado crítico con sepsis severa o shock séptico ha permanecido elevada a pesar de diferentes innovaciones terapéuticas, el uso temprano y adecuado de medidas de reanimación, esquemas antimicrobianos ajustados a guías y la aplicación estricta de paquetes terapéuticos con metas en diferentes horas de ingreso o diagnóstico del paciente. El uso de la inmunomodulación ha sido controvertida en los últimos años por protocolos internacionales y diferentes revisiones de la literatura, sin embargo nuevos estudios del uso de inmunoglobulina G enriquecida con inmunoglobulinas M y A han revivido el debate. Se presenta una revisión actual de los pros, contras y el uso óptimo de la inmunoglobulina G enriquecida con inmunoglobulina M.
Palabras clave:
Sepsis severa
Shock séptico
Inmunomodulación
Inmunoglobulina G enriquecida
Mortalidad
Abstract
The mortality of critically ill patients with severe sepsis or septic shock has remained high despite different therapeutic innovations, the early and appropriate use of resuscitation measures, antimicrobial therapy adjusted to guidelines, and strict application of therapeutic packages at different admission times or patient diagnosis. The use of immunomodulation has been controversial in recent years, with international protocols and various literature reviews. However new studies on the use of immunoglobulin G enriched immunoglobulin M and A (IgA) have revived the debate. A current review of the pros, cons, and optimal use of enriched immunoglobulin G immunoglobulin M is presented.
Keywords:
Severe sepsis
Septic shock
Immunomodulation
Immunoglobulin G enriched
Mortality
Artículo
Opciones para acceder a los textos completos de la publicación Acta Colombiana de Cuidado Intensivo
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, M.R. Pinsky.
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.
Crit Care Med., 29 (2001), pp. 1303-1310
[2]
P.A. Danai, M. Moss, D.M. Mannino, G.S. Martin.
The epidemiology of sepsis in patients with malignancy.
Chest., 129 (2006), pp. 1432-1440
[3]
S.K. Cribbs, G.S. Martin.
Expanding the global epidemiology of sepsis [Internet].
Crit Care Med., 35 (2007), pp. 2646-2648
[5]
S. Gupta, M. Jonas.
Sepsis, septic shock and multiple organ failure.
Anaesth Intensive Care Med., 7 (2006), pp. 143-146
[6]
F. Gutiérrez.
Importancia de la edad avanzada en las infecciones: mitos y realidades.
Enferm Infecc Microbiol Clin., 25 (2007), pp. 609-611
[7]
D.M. Berkowitz, G.S. Martin.
Disparities in sepsis: what do we understand?.
Crit Care Med., 35 (2007), pp. 958-960
[8]
J.L. Vincent, S. Opal, S.M. Opal, J.C. Marshall, K.J. Tracey.
Sepsis definitions: time for change.
Lancet, 381 (2013), pp. 774-775
[9]
T.S. Wang, J.C. Deng.
Molecular and cellular aspects of sepsis-induced immunosuppression.
J Mol Med., 86 (2008), pp. 495-506
[10]
R.S. Hotchkiss, I.E. Karl.
The pathophysiology and treatment of sepsis.
N Engl J Med., 348 (2003), pp. 138-150
[11]
A. Ashare, L.S. Powers, N.S. Butler, K.C. Doerschug, M.M. Monick, G.W. Hunninghake.
Anti-inflammatory response is associated with mortality and severity of infection in sepsis.
Am J Physiol Lung Cell Mol Physiol., 288 (2005), pp. L633-L640
[12]
L. Doughty, J.A. Carcillo, S. Kaplan, J. Janosky.
The compensatory anti-inflammatory cytokine interleukin 10 response in pediatric sepsis-induced multiple organ failure.
Chest., 113 (1998), pp. 1625-1631
[13]
H.G. Gomez, S.M. Gonzalez, J.M. Londoño, N.A. Hoyos, C.D. Niño, A.L. León, et al.
Immunological characterization of compensatory anti-inflammatory response syndrome in patients with severe sepsis: a longitudinal study*.
Crit Care Med, 42 (2014), pp. 771-780
[14]
G. Ortiz, C. Dueñas, F. Rodríguez, L. Barrera, G. De La Rosa, R. Dennis, et al.
Epidemiology of sepsis in Colombian intensive care units.
Biomédica., 34 (2014), pp. 40-47
[15]
J.J. Armstrong, J. Baddiley, J.G. Buchanan, A.L. Davison, M.V. Keleman, F.C. Neuhaus.
Composition of teichoic acids from a number of bacterial walls.
Nature., 25 (1959), pp. 247-248
[16]
S.R. Townsend, C. Schorr, M.M. Levy, R.P. Dellinger.
Reducing mortality in severe sepsis: The surviving sepsis campaign.
Clin Chest Med, 29 (2008), pp. 721-733
[17]
R.P. Dellinger, J.M. Carlet, H. Masur, H. Gerlach, T. Calandra, J. Cohen, Surviving sepsis campaign management guidelines committee:, et al.
Surviving sepsis campaign guidelines for management of severe sepsis and septic shock.
Crit Care Med, 32 (2004), pp. 858-873
[18]
R.P. Dellinger, M.M. Levy, J.M. Carlet, J. Bion, M.M. Parker, R. Jaeschke, et al.
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Intensive Care Med, 34 (2008), pp. 17-60
[19]
M.M. Levy, R.P. Dellinger, S.R. Townsend, W.T. Linde-Zwirble, J.C. Marshall, J. Bion, et al.
The surviving sepsis campaign: Results of an international guideline-based performance improvement program targeting severe sepsis.
Crit Care Med, 38 (2010), pp. 367-374
[20]
R. Ferrer, A. Artigas, M.M. Levy, J. Blanco, G. González-Díaz, J. Garnacho-Montero, Edusepsis Study Group.
Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain.
JAMA, 299 (2008), pp. 2294-2303
[21]
A.V. Barochia, X. Cui, D. Vitberg, A.F. Suffredini, N.P. O’Grady, S.M. Banks, et al.
Bundled care for septic shock: An analysis of clinical trials.
Crit Care Med, 38 (2010), pp. 668-678
[22]
A. Castellanos-Ortega, B. Suberviola, L.A. García-Astudillo, M.S. Holanda, F. Ortiz, J. Llorca, et al.
Impact of the surviving sepsis campaign protocols on hospital length of stay and mortality in septic shock patients: Results of a three-year follow-up quasi-experimental study.
Crit Care Med, 38 (2010), pp. 1036-1043
[23]
K. Jeon, T.G. Shin, M.S. Sim, G.Y. Suh, S.Y. Lim, H.G. Song, et al.
Improvements in compliance with resuscitation bundles and achievement of end points after an educational program on the management of severe sepsis and septic shock.
Shock, 37 (2012), pp. 463-467
[24]
A. Van Zanten, R. Arthur, S. Brinkman, S. Arbous, A. Abu-Hanna, M.M. Levy, et al.
Guideline bundles adherence and mortality in severe sepsis and septic shock.
Crit Care Med, 42 (2014), pp. 1890-1898
[25]
J. Salinas, A. Fica.
Inmunoglobulinas en sepsis y shock séptico.
Rev Chil Infect, 22 (2005), pp. 21-31
[26]
Z. Molnár, A. Nierhaus, F. Esen.
Immunoglobulins in sepsis: Which patients will benefit the most? Annual Update in Intensive Care and Emergency Medicine 2013.
Springer-Verlag, (2013), pp. 145-152
[27]
INVIMA. Disponible en:http://web.sivicos.gov.co:8080/consultas/consultas/consreg_encabcum.jsp.
[28]
M.M. Alejandria, M.A. Lansang, L.F. Dans, J.B. Mantaring.
Intravenous immunoglobulin for treating sepsis and septic shock.
Cochrane Database Syst Rev., (2002), pp. CD001090
[29]
J. Pildal, P.C. Gøtzsche.
Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review.
Clin Infect Dis., 39 (2004), pp. 38-46
[30]
A.R. Neilson, H. Burchardi, H. Schneider.
Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock.
J Crit Care., 20 (2005), pp. 239-249
[31]
A. Norrby-Teglund, K.N. Haque, L. Hammarström.
Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical effi cacy in relation to microbiological aetiology and severity of sepsis.
J Intern Med., 260 (2006), pp. 509-516
[32]
A.F. Turgeon, B. Hutton, D.A. Fergusson, L. McIntyre, A.A. Tinmouth, D.W. Cameron, et al.
Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis.
Ann Intern Med., 146 (2007), pp. 193-203
[33]
K.B. Laupland, A.W. Kirkpatrick, A. Delaney.
Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis.
Crit Care Med, 35 (2007), pp. 2686-2692
[34]
K.G. Kreymann, G. de Heer, A. Nierhaus, S. Kluge.
Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock.
Crit Care Med., 35 (2007), pp. 2677-2685
[35]
R. Dellinger, M. Levy, A. Rhodes, D. Annane, H. Gerlach, S.M. Opal, et al.
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.
Crit Care Med., 42 (2013), pp. 580-637
[36]
K. Werdan, G. Pilz, O. Bujdoso, P. Fraunberger, G. Neeser, R.E. Schmieder, Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group, et al.
Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study.
Crit Care Med, 35 (2007), pp. 2693-2701
[37]
E.R. Burns, V. Lee, A. Rubinstein.
Treatment of septic thrombocytopenia with immune globulin.
J Clin Immunol, 11 (1991), pp. 363-368
[38]
J. Darenberg, N. Ihendyane, J. Sjölin, E. Aufwerber, S. Haidl, P. Follin, StreptIg Study Group.
Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial.
Clin Infect Dis, 37 (2003), pp. 333-340
[39]
M. Hentrich, K. Fehnle, H. Ostermann, J. Kienast, O. Cornely, C. Salat, et al.
IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial.
Crit Care Med, 34 (2006), pp. 1319-1325
[40]
A. Rodríguez, J. Rello, J. Neira, B. Maskin, D. Ceraso, L. Vasta, et al.
Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery.
Shock, 23 (2005), pp. 298-304
[41]
K. Werdan.
Immunoglobulin treatment in sepsis-Is the answer no?.
Crit Care Med, 34 (2006),
[42]
G. Berlot, M. Vassallo, N. Busetto, M. Bianchi, F. Zornada, I. Rosato, et al.
Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: A retrospective analysis.
Journal of Critical Care., 27 (2012), pp. 167-171
[43]
L. Yavuz, G. Aynali, A. Aynali, A. Alaca, S. Kutuk, B.G. Ceylan.
The effects of adjuvant immunoglobulin M-enriched immunoglobulin therapy on mortality rate and renal function in sepsisinduced multiple organ dysfunction syndrome: retrospective analysis of Intensive Care Unit patients.
J Int Med Res., 40 (2012), pp. 1166
[44]
I. Cavazzuti, G. Serafini, S. Busani, L. Rinaldi, E. Biagioni, M. Buoncristiano, et al.
Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock.
Intensive Care Med., 40 (2014), pp. 1888-1896
[45]
J. Carapetis, P. Jacoby, K. Carville, S.J. Ang, N. Curtis, R. Andrews.
Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group A Streptococcal infections.
CID, 59 (2014), pp. 358-365
